Sanofi-aventis announced today results of a study which demonstrated that patients using Lantus® (insulin glargine injection) once-daily and Apidra® (insulin glulisine injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin. Two abstracts from this study were highlighted at the stars and stripes insulin-dependent diabetes mellitus Association's 70th Annual Scientific Sessions (ADA).

More: - The rest...